标题
The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
作者
关键词
-
出版物
Biomedicines
Volume 9, Issue 8, Pages 1051
出版商
MDPI AG
发表日期
2021-08-19
DOI
10.3390/biomedicines9081051
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The roles of STAT6 in regulating B cell fate, activation, and function
- (2021) Wei Wang et al. IMMUNOLOGY LETTERS
- JAK-STAT in Early Hematopoiesis and Leukemia
- (2021) Eirini Sofia Fasouli et al. Frontiers in Cell and Developmental Biology
- Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia
- (2021) Tamer A Othman et al. Future Oncology
- Role of STAT3 signaling pathway in breast cancer
- (2020) Jia-hui Ma et al. Cell Communication and Signaling
- A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
- (2020) Prithviraj Bose et al. LEUKEMIA
- Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers
- (2020) Marie Brachet-Botineau et al. Cancers
- JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
- (2020) Azucena Salas et al. Nature Reviews Gastroenterology & Hepatology
- Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia
- (2020) Theodore P. Braun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue
- (2020) Doris Kaltenecker et al. Molecular Metabolism
- Small Molecule Inhibitor C188-9 Synergistically Enhances the Demethylated Activity of Low-Dose 5-Aza-2′-Deoxycytidine Against Pancreatic Cancer
- (2020) Rui Kong et al. Frontiers in Oncology
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
- (2020) Moshe Talpaz et al. LEUKEMIA
- The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib
- (2020) Anand A. Patel et al. Current Hematologic Malignancy Reports
- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology
- (2019) Carlota Recio et al. ONCOGENE
- C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma
- (2019) Jian-Xin Di et al. ANTI-CANCER DRUGS
- Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
- (2019) Jae Yoon Jeon et al. INVESTIGATIONAL NEW DRUGS
- Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia
- (2019) Abhinav Dhall et al. Frontiers in Oncology
- NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia
- (2019) Alina Rudorf et al. BLOOD
- Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage
- (2019) Silei Bi et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
- (2019) Christina D. Drenberg et al. Nature Communications
- JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia
- (2019) Sangeetha Venugopal et al. BLOOD REVIEWS
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- The potential and controversy of targeting STAT family members in cancer
- (2019) Yannick Verhoeven et al. SEMINARS IN CANCER BIOLOGY
- JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation
- (2019) Dagmar Gotthardt et al. Frontiers in Immunology
- Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001–2013
- (2018) Xiaolu Song et al. ACTA HAEMATOLOGICA
- The regulation of JAKs in cytokine signaling and its breakdown in disease
- (2018) Henrik M. Hammarén et al. CYTOKINE
- Pharmacologic inhibition of STAT5 in acute myeloid leukemia
- (2018) Bettina Wingelhofer et al. LEUKEMIA
- Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer
- (2018) Bettina Wingelhofer et al. LEUKEMIA
- Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes
- (2018) Mona M. Hosseini et al. LEUKEMIA
- Somatic mutations precede acute myeloid leukemia years before diagnosis
- (2018) Pinkal Desai et al. NATURE MEDICINE
- The molecular basis of JAK/STAT inhibition by SOCS1
- (2018) Nicholas P. D. Liau et al. Nature Communications
- Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
- (2018) Ilkka S. Junttila Frontiers in Immunology
- Comprehensive genetic diagnosis of acute myeloid leukemia by next generation sequencing
- (2018) Elisabeth K.M. Mack et al. HAEMATOLOGICA
- Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
- (2018) Grzegorz Helbig MEDICAL ONCOLOGY
- Prediction of acute myeloid leukaemia risk in healthy individuals
- (2018) Sagi Abelson et al. NATURE
- Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
- (2018) Aditi Shastri et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Utility Of A Next-Generation Sequencing Panel For Acute Myeloid Leukemia Diagnostics
- (2018) Carmen M. Alonso et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
- (2018) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation
- (2018) Guo-Juan Niu et al. Frontiers in Immunology
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
- (2018) Matthew J. Reilley et al. Journal for ImmunoTherapy of Cancer
- Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
- (2017) Karoline V. Gleixner et al. HAEMATOLOGICA
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Morphologic and Molecular Characteristics of De Novo AML WithJAK2V617F Mutation
- (2017) Juliana E. Hidalgo-López et al. Journal of the National Comprehensive Cancer Network
- Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
- (2017) Davide Genini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STAT5A/5B-specific expansion and transformation of hematopoietic stem cells
- (2017) S Ghanem et al. Blood Cancer Journal
- Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
- (2017) Karoline V. Gleixner et al. HAEMATOLOGICA
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
- (2017) Ryan Ferrao et al. Frontiers in Endocrinology
- Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia
- (2016) Q. Zhang et al. BLOOD
- Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
- (2016) K. H. Metzeler et al. BLOOD
- A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
- (2016) Steven Knapper et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers
- (2016) W. C. Chen et al. CANCER RESEARCH
- A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells
- (2016) Yoshinori Ishikawa et al. MOLECULAR CANCER THERAPEUTICS
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute myeloid leukemia: advancing clinical trials and promising therapeutics
- (2016) Naval Daver et al. Expert Review of Hematology
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’
- (2016) I De Kouchkovsky et al. Blood Cancer Journal
- DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
- (2016) Hanae Sato et al. Frontiers in Oncology
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
- (2015) Michinori Ogura et al. CANCER SCIENCE
- A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- (2015) Naveen Pemmaraju et al. Clinical Lymphoma Myeloma & Leukemia
- Essential role of endocytosis for interleukin-4-receptor-mediated JAK/STAT signalling
- (2015) K. Kurgonaite et al. JOURNAL OF CELL SCIENCE
- STAT5A regulates DNMT3A in CD34+/CD38− AML cells
- (2015) Asako Takeuchi et al. LEUKEMIA RESEARCH
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells
- (2014) A. M. Cook et al. BLOOD
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
- (2014) R. C. Lindsley et al. BLOOD
- Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients
- (2014) R Kihara et al. LEUKEMIA
- Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase
- (2014) Yibing Shan et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer
- (2014) Z Ren et al. ONCOGENE
- Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition
- (2014) P. J. Lupardus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia
- (2014) Øystein Bruserud et al. Expert Review of Hematology
- Role of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression
- (2014) Jamie Williams et al. Cells
- Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
- (2013) O. Abdel-Wahab et al. BLOOD
- The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges
- (2013) A. P. Hutchins et al. Briefings in Functional Genomics
- Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study
- (2013) Anjali Shah et al. BRITISH JOURNAL OF HAEMATOLOGY
- Outcome of older patients with acute myeloid leukemia
- (2013) Mya S. Thein et al. CANCER
- Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia
- (2013) M A Dawson et al. LEUKEMIA
- FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
- (2013) Sabine Kayser et al. LEUKEMIA & LYMPHOMA
- SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition
- (2013) Nadia J Kershaw et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report
- (2012) M. S. Redell et al. BLOOD
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- The role of STAT5 in lymphocyte development and transformation
- (2012) Lynn M Heltemes-Harris et al. CURRENT OPINION IN IMMUNOLOGY
- Age-Related Prognostic Impact of Different Types ofDNMT3AMutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
- (2012) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor
- (2011) M. S. Redell et al. BLOOD
- Transcriptional regulation by STAT6
- (2011) Shreevrat Goenka et al. IMMUNOLOGIC RESEARCH
- Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas
- (2011) Camilla Pilati et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity
- (2011) Brent D. G. Page et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
- (2011) S Hart et al. Blood Cancer Journal
- Regulation of hematopoietic cell development and function by Stat3
- (2010) Pamela et al. Frontiers in Bioscience-Landmark
- High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V
- (2010) Robert Fritsche-Polanz et al. Molecular Oncology
- Alternative Activation of Macrophages: An Immunologic Functional Perspective
- (2008) Fernando O. Martinez et al. Annual Review of Immunology
- Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B
- (2008) L. Hennighausen et al. GENES & DEVELOPMENT
- Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the ‘second hit’ hypothesis
- (2008) H Becker et al. LEUKEMIA
- Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia
- (2008) Sampa Ghoshal (Gupta) et al. LEUKEMIA RESEARCH
- Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells
- (2008) Angela Colmone et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation